NASDAQ · MNMD
Healthcare · Biotechnology
$20.69
Up+$0.09 (+0.44%)
Updated Nov 4, 2026, 5:51 PM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · MNMD
1M range · 0 trading sessions · Daily adjusted prices
MNMD does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning MNMD.
Company
Market Activity
Research & News
MNMD research
Company profile and research snapshot.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Dec 23, 2025 | Jones Trading | Buy | — |
| Nov 7, 2025 | Canaccord Genuity | Buy | — |
| Nov 7, 2025 | RBC Capital | Outperform | — |
| Oct 13, 2025 | Needham | Buy | — |
| Aug 4, 2025 | Oppenheimer | Outperform | — |
No generated briefing is available yet.
Benzinga · Oct 29, 2026
https://www.marijuanamoment.net/new-bill-in-congress-would-dramatically-overhaul-how-the-federal-government-classifies-drugs-while-legalizing-marijuana/
SeekingAlpha · Jan 14, 2026
Mind Medicine (MindMed) Inc. (MNMD) 44th Annual J.P.
businesswire.com · Dec 1, 2025
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to four newly hired non-executive employees consisting of options to purchase an aggregate of 182,100 common shares of the Company (the “Options”) with effective grant dates of November 17, 2025, November 24, 2025 and December 1, 2.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning MNMD.
